Intravenous diuretic therapy is the current standard of care for hypervolemic heart failure, but loop diuretics decrease in effectiveness with repeated use. In addition, several studies have ...

“This report will provide confidence for placing patients with chronic hyponatremia due to SIADH or hypervolemic conditions such as CHF and cirrhosis on a V2-receptor antagonist,” concludes Berl.

The basic experimental model tested the ability of an infusion of human plasma to expand the normal plasma volume to a hypervolemic state and to maintain this expansion for several hours.

Using bioelectrical impedance analysis, researchers classified patients into hypovolemic, euvolemic and hypervolemic groups based on fluid status. BP patterns were determined using 24-hour BP ...

Chicago, IL - Results of two trials of tolvaptan (Otsuka America Pharmaceutical), a novel oral vasopressin V2-receptor antagonist, show that treatment effectively increased serum sodium ...

VAPRISOL (conivaptan) 20mg/ampule by Astellas Pharma Vaprisol (conivaptan HCl, from Astellas Pharma) Premixed injection, an arginine vasopressin (AVP) receptor antagonist, is available for the ...

The FDA has approved an intravenous drug for hospital patients suffering from potentially life-threateningly low sodium levels, the drug's manufacturer said Friday. Astellas Pharma US Inc.

Deerfield, IL - Astellas Pharma announced that the US Food and Drug Administration (FDA) has approved conivaptan hydrochloride injection (Vaprisol), an arginine vasopressin antagonist, for the ...

Overall, the incidence of euvolemic or hypervolemic hyponatremia was 54%. The hyponatremia incidence was highest (76%) among patients with small-cell and non-small cell lung cancer; 37% for ...